Use of electrochemical oxidation and model peptides to study nucleophilic biological targets of reactive metabolites: The case of rimonabant

Chemical Research in Toxicology

Volumn 27, Issue 10, 2014, Pages 1808-1820

  Thorsell, Annika ^a   Isin, Emre M ^a   Jurva, Ulrik ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE; AMINE; CYANIDE; CYTOCHROME P450; METHOXYAMINE; RIMONABANT; ANGIOTENSIN II; BOVINE SERUM ALBUMIN; ENKEPHALINAMIDE-LEU, ALA(2)-; ENKEPHALIN[2 ALANINE 5 LEUCINE]; PEPTIDE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG PROTEIN BINDING; ELECTROCHEMICAL ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; MALE; METABOLITE; NUCLEOPHILICITY; OXIDATION; PROTEIN MODIFICATION; AMINO ACID SEQUENCE; ANALOGS AND DERIVATIVES; ANIMAL; BOVINE; CHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; OXIDATION REDUCTION REACTION; TANDEM MASS SPECTROMETRY;

AMINO ACID SEQUENCE; ANGIOTENSIN II; ANIMALS; CATTLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ELECTROCHEMICAL TECHNIQUES; ENKEPHALIN, LEUCINE-2-ALANINE; HUMANS; MICROSOMES, LIVER; OXIDATION-REDUCTION; PEPTIDES; PIPERIDINES; PYRAZOLES; SERUM ALBUMIN, BOVINE; TANDEM MASS SPECTROMETRY;

EID: 84908056750     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx500255r     Document Type: Article

References (52)

1. Miller, J. A., and Miller, E. C. (1947) The metabolism and carcinogenicity of p-dimethylaminoazobenzene and related compounds in the rat. Cancer Res. 7, 39-41.
2. Obach, R. S., Kalgutkar, A. S., Soglia, J. R., and Zhao, S. X. (2008) Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem. Res. Toxicol. 21, 1814-1822.
3. Thompson, R. A., Isin, E. M., Li, Y., Weidolf, L., Page, K., Wilson, I., Swallow, S., Middleton, B., Stahl, S., Foster, A. J., Dolgos, H., Weaver, R., and Kenna, J. G. (2012) In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs. Chem. Res. Toxicol. 25, 1616-1632.
4. Uetrecht, J. (2008) Idiosyncratic drug reactions: past, present, and future. Chem. Res. Toxicol. 21, 84-92.
5. Baillie, T. A. (2008) Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem. Res. Toxicol. 21, 129-137.
6. Aloysius, H., Tong, V. W., Yabut, J., Bradley, S. A., Shang, J., Zou, Y., and Tschirret-Guth, R. A. (2012) Metabolic activation and major protein target of a 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonist. Chem. Res. Toxicol. 25, 1412-1422.
7. Koen, Y. M., Sarma, D., Hajovsky, H., Galeva, N. A., Williams, T. D., Staudinger, J. L., and Hanzlik, R. P. (2013) Protein targets of thioacetamide metabolites in rat hepatocytes. Chem. Res. Toxicol. 26, 564-574.
8. Meng, X., Howarth, A., Earnshaw, C. J., Jenkins, R. E., French, N. S., Back, D. J., Naisbitt, D. J., and Park, B. K. (2013) Detection of drug bioactivation in vivo: mechanism of nevirapine-albumin conjugate formation in patients. Chem. Res. Toxicol. 26, 575-583.
9. Mitrea, N., LeBlanc, A., St-Onge, M., and Sleno, L. (2010) Assessing covalent binding of reactive drug metabolites by complete protein digestion and LC-MS analysis. Bioanalysis 2, 1211-1221.
10. Tzouros, M., and Pahler, A. (2009) A targeted proteomics approach to the identification of peptides modified by reactive metabolites. Chem. Res. Toxicol. 22, 853-862.
11. VandenBrink, B. M., Davis, J. A., Pearson, J. T., Foti, R. S., Wienkers, L. C., and Rock, D. A. (2012) Cytochrome p450 architecture and cysteine nucleophile placement impact raloxifene-mediated mechanism-based inactivation. Mol. Pharmacol. 82, 835-842.
12. Zhang, H., Amunugama, H., Ney, S., Cooper, N., and Hollenberg, P. F. (2011) Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme. Mol. Pharmacol. 80, 839-847.
13. Lin, H. L., Kenaan, C., and Hollenberg, P. F. (2012) Identification of the residue in human CYP3A4 that is covalently modified by bergamottin and the reactive intermediate that contributes to the grapefruit juice effect. Drug Metab. Dispos. 40, 998-1006.
14. Boerma, J. S., Vermeulen, N. P., and Commandeur, J. N. (2011) Application of CYP102A1M11H as a tool for the generation of protein adducts of reactive drug metabolites. Chem. Res. Toxicol. 24, 1263-1274.
15. Lohmann, W., Hayen, H., and Karst, U. (2008) Covalent protein modification by reactive drug metabolites using online electrochemistry/liquid chromatography/mass spectrometry. Anal. Chem. 80, 9714-9719.
16. Hettick, J. M., Siegel, P. D., Green, B. J., Liu, J., and Wisnewski, A. V. (2012) Vapor conjugation of toluene diisocyanate to specific lysines of human albumin. Anal. Biochem. 421, 706-711.
17. Pham, N. T., Jewell, W. T., Morin, D., Jones, A. D., and Buckpitt, A. R. (2012) Characterization of model peptide adducts with reactive metabolites of naphthalene by mass spectrometry. PLoS One 7, e42053.
18. Yukinaga, H., Iwabuchi, H., Okazaki, O., and Izumi, T. (2012) Glutathione S-transferase pi trapping method for generation and characterization of drug-protein adducts in human liver microsomes using liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 67-68, 186-192.
19. Jahn, S., Faber, H., Zazzeroni, R., and Karst, U. (2012) Electrochemistry/mass spectrometry as a tool in the investigation of the potent skin sensitizer p-phenylenediamine and its reactivity toward nucleophiles. Rapid Commun. Mass Spectrom. 26, 1453-1464.
20. Obach, R. S., and Van Vunakis, H. (1988) Non-metabolic covalent binding of nicotine-delta 1′(5′)-iminium ion to liver microsomes and sulfhydryl-containing polyamino acids. Biochem. Pharmacol. 37, 4601-4604.
21. Jurva, U., Wikstrom, H. V., Weidolf, L., and Bruins, A. P. (2003) Comparison between electrochemistry/mass spectrometry and cytochrome P450 catalyzed oxidation reactions. Rapid Commun. Mass Spectrom. 17, 800-810.
22. Johansson, T., Weidolf, L., and Jurva, U. (2007) Mimicry of phase I drug metabolism?novel methods for metabolite characterization and synthesis. Rapid Commun. Mass Spectrom. 21, 2323-2331.
23. Lohmann, W., and Karst, U. (2008) Biomimetic modeling of oxidative drug metabolism: Strategies, advantages and limitations. Anal. Bioanal Chem. 391, 79-96.
24. Jahn, S., and Karst, U. (2012) Electrochemistry coupled to (liquid chromatography/) mass spectrometry - current state and future perspectives. J. Chromatogr., A 1259, 16-49.
25. Nouri-Nigjeh, E., Bischoff, R., Bruins, A. P., and Permentier, H. P. (2011) Electrochemistry in the mimicry of oxidative drug metabolism by cytochrome P450s. Curr. Drug Metab. 12, 359-371.
26. Madsen, K. G., Olsen, J., Skonberg, C., Hansen, S. H., and Jurva, U. (2007) Development and evaluation of an electrochemical method for studying reactive phase-I metabolites: correlation to in vitro drug metabolism. Chem. Res. Toxicol. 20, 821-831.
27. Deng, H., and VanBerkel, G. J. (1999) A Thin-Layer Flow Cell Coupled On-Line with Electrospray-Mass Spectrometry for the Study of Biological Redox Reactions. Electroanalysis 11, 857.
28. Volk, K. J., Yost, R. A., and Brajter-Toth, A. (1992) Electrochemistry On Line with Mass Spectrometry: Insight into Biological Redox Reactions. Anal. Chem. 64, 21A.
29. Johansson, T., Jurva, U., Gronberg, G., Weidolf, L., and Masimirembwa, C. (2009) Novel metabolites of amodiaquine formed by CYP1A1 and CYP1B1: structure elucidation using electrochemistry, mass spectrometry, and NMR. Drug Metab. Dispos. 37, 571-579.
30. Mali'n, T. J., Weidolf, L., Castagnoli, N., Jr, and Jurva, U. (2010) P450-catalyzed vs. electrochemical oxidation of haloperidol studied by ultra-performance liquid chromatography/electrospray ionization mass spectrometry. Rapid Commun. Mass Spectrom. 24, 1231-1240.
31. Getek, T. A., Korfmacher, W. A., McRae, T. A., and Hinson, J. A. (1989) Utility of solution electrochemistry mass spectrometry for investigating the formation and detection of biologically important conjugates of acetaminophen. J. Chromatogr. 474, 245-256.
32. Boyd, S. T., and F, B. (2006) Update on rimonabant - a selective cannabinoid CB1 antagonist. Ann. Pharmacother. 40, 994.
33. Boyd, S. T., and Fremming, B. A. (2005) Rimonabant - a selective CB1 antagonist. Ann. Pharmacother. 39, 684-690.
34. Henness, S., Robinson, D. M., and Lyseng-Williamson, K. A. (2006) Rimonabant. Drugs 66, 2109-2119 (discussion 2120-2121).
35. Christensen, R., Kristensen, P. K., Bartels, E. M., Blidda, H., and Astrup, A. (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370, 1706-1713.
36. Andresen-Bergstrom, M. A., Isin, E. M., Castagnoli, J. N., and Milne, C. E. (2011) Bioactivation pathways of the cannabinoid receptor 1 antagonist rimonabant. Drug Metab. Dispos. 39, 1823-1832.
37. Foster, A. J., Greer, M. L., Coates, R., Smith, T. J. D., and Kenna, J. G. (2010) In vitro investigation of the role of cyp dependent metabolism in drug hepatotoxicity using the THLE-CYP cell panel. Toxicology 278, 355-356.
38. Hanzlik, R. P., Koen, Y. M., Theertham, B., Dong, Y., and Fang, J. (2007) The reactive metabolite target protein database (TPDB) - a web-accessible resource. BMC Bioinf. 8, 95.
39. Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., and Baillie, T. A. (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17, 3-16.
40. Argoti, D., Liang, L., Conteh, A., Chen, L., Bershas, D., Yu, C. P., Vouros, P., and Yang, E. (2005) Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry (LCMS/MS). Chem. Res. Toxicol. 18, 1537-1544.
41. Antunes, A. M., Godinho, A. L., Martins, I. L., Justino, G. C., Beland, F. A., and Marques, M. M. (2010) Amino acid adduct formation by the nevirapine metabolite, 12-hydroxynevirapine - a possible factor in nevirapine toxicity. Chem. Res. Toxicol. 23, 888-899.
42. Charneira, C., Grilo, N. M., Pereira, S. A., Godinho, A. L., Monteiro, E. C., Marques, M. M., and Antunes, A. M. (2012) N-terminal valine adduct from the anti-HIV drug abacavir in rat haemoglobin as evidence for abacavir metabolism to a reactive aldehyde in vivo. Br. J. Pharmacol. 167, 1353-1361.
43. Hettick, J. M., Ruwona, T. B., and Siegel, P. D. (2009) Structural elucidation of isocyanate-peptide adducts using tandem mass spectrometry. J. Am. Soc. Mass Spectrom. 20, 1567-1575.
44. Gasthuys, M., Alves, S., and Tabet, J. C. (2005) N-terminal adducts of bovine hemoglobin with glutaraldehyde in a hemoglobin-based oxygen carrier. Anal. Chem. 77, 3372-3378.
45. Jurva, U., Bissel, P., Isin, E. M., Igarashi, K., Kuttab, S., and Castagnoli, N., Jr (2005) Model electrochemical-mass spectrometric studies of the cytochrome P450-catalyzed oxidations of cyclic tertiary allylamines. J. Am. Chem. Soc. 127, 12368-12377.
46. Avent, K. M., DeVoss, J. J., and Gillam, E. M. (2006) Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites. Chem. Res. Toxicol. 19, 914-920.
47. Dalvie, D. K., and O'Connell, T. N. (2004) Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes P450, and monoamine oxidases. Drug Metab. Dispos. 32, 49-57.
48. Owens, S. M., Gunnell, M., Laurenzana, E. M., and Valentine, J. L. (1993) Dose- and time-dependent changes in phencyclidine metabolite covalent binding in rats and the possible role of CYP2D1. J. Pharmacol. Exp. Ther. 265, 1261-1266.
49. Castagnoli, N., Rimoldi, J. M., Bloomquist, J., and Castagnoli, K. P. (1997) Potential Metabolic Bioactivation Pathways Involving Cyclic Tertiary Amines and Azaarenes. Chem. Res. Toxicol. 10, 924-940.
50. Henderson, A. P., Bleasdale, C., Clegg, W., and Golding, B. T. (2004) 2,6-Diarylaminotetrahydropyrans from Reactions of Glutaraldehyde with Anilines: Models for Biomolecule Cross-Linking. Chem. Res. Toxicol. 17, 378-382.
51. Furst, W., and Banerjee, A. (2005) Release of glutaraldehyde from an albumin-glutaraldehyde tissue adhesive causes significant in vitro and in vivo toxicity. Ann. Thorac. Surg. 79, 1522-1528 (discussion 1529).
52. Migneault, I., Dartiguenave, C., Bertrand, M. J., and Waldron, K. C. (2004) Glutaraldehyde: behavior in aqueous solution, reaction with proteins, and application to enzyme crosslinking. BioTechniques 37 (790-796), 798-802.